Reblozyl 75 MG vials

Ended Awarded Last action

Contract number
SPE2DR26FT9PB
Awardee
Awarding agency
Obligated
$17,329

Award facts

Contract value 100% obligated
$17,329.22 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
424210 Drugs and Druggists' Sundries Merchant Wholesalers
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Conshohocken, PA 19428, USA

Award details come from SAM.gov/FPDS.

About this award

The Defense Logistics Agency issued a $17,329.22 delivery order to Amerisourcebergen Drug Corp on April 23, 2026, for 75 mg vials of Reblozyl (luspatercept), a specialty pharmaceutical for treating anemia associated with myelodysplastic syndromes.

Place of performance is Conshohocken, PA. Ultimate completion date is May 14, 2026. The order is priced on a firm fixed-price basis with no set-aside. Amerisourcebergen operates as a pharmaceutical distributor and medical supplier under its parent company Cencora, Inc., competing on full-and-open competitive basis for Defense Health Agency and military medical facility supply across domestic and overseas locations.

Quick answers

Who was awarded contract SPE2DR26FT9PB?

SPE2DR26FT9PB was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on April 23, 2026.

How much is contract SPE2DR26FT9PB worth?

The government has obligated $17,329 on SPE2DR26FT9PB.

Is contract SPE2DR26FT9PB an order under another contract?

Yes. SPE2DR26FT9PB is a delivery order under SPE2DR25D3201, an indefinite delivery contract.

Was contract SPE2DR26FT9PB competed?

The extent of competition for SPE2DR26FT9PB was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award